Condition: Lung Transplant · Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
The purpose of this study is to see if taking the study drug, Belumosudil, for 52 weeks in addition to your usual care and medication, will prevent Chronic Lung Allograft Dysfunction (CLAD) in participants who have a lung biopsy that shows evidence of rejection or inflammation to the transplanted lung(s). For this study, biopsies that show evidence of Acute Rejection (AR), Lymphocytic Bronchiolitis (LB), Organizing Pneumonia (OP) or Acute Lung Injury (ALI) are referred to as "Qualifying Biopsies"; patients who had evidence of one or more of these conditions on a recent biopsy are eligible for enrollment in this study. Belumosudil is an investigational drug that blocks a molecule in the body that reduces inflammation and scarring and may play a role in the development and progression of CLAD. Belumosudil is a drug approved by the FDA to treat adults and children 12 years and older with chronic graft-versus-host disease (cGVHD), a condition with some similarities to CLAD. The primary objective it to determine the efficacy of treatment with Belumosudil + maintenance immunosuppression (IS) versus placebo + maintenance IS on preventing the subsequent development of probable or definite CLAD, lung retransplant, or death.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of California, Los Angeles (Site #: 71123) | Los Angeles, California, United States | Recruiting |
| Stanford University (Site #: 71141) | Palo Alto, California, United States | Recruiting |
| Johns Hopkins (Site #: 71119) | Baltimore, Maryland, United States | Recruiting |
| University of Minnesota (Site 71151) | Minneapolis, Minnesota, United States | Recruiting |
| Washington University (Site #: 71157) | St Louis, Missouri, United States | Recruiting |
| NYU Langone Health (Site #: 71177) | New York, New York, United States | Recruiting |
| Duke University (Site #: 71139) | Durham, North Carolina, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center (Site #: 71017) | Cincinnati, Ohio, United States | Recruiting |
| Cleveland Clinic (Site #: 71101) | Cleveland, Ohio, United States | Recruiting |
| University of Pennsylvania (Site #: 71111) | Philadelphia, Pennsylvania, United States | Recruiting |
| Vanderbilt University Medical Center (Site #: 71174) | Nashville, Tennessee, United States | Recruiting |
| University Health Network/Toronto General Hospital (Site #: 71121) | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06476132